acquired
Stage
1
Investors
About
KalVista Pharmaceuticals develops orally-delivered small molecule medicines primarily focused on hereditary angioedema (HAE), aiming to improve treatment options for patients with rare diseases.
Explore Kalvista Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.